PATENT CLAIM ANALYSIS

Application Number: 16403288
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-08
Patent Classification: ["514", "237500"]

Abstract:
Improved methods of treating multiple sclerosis and/or psoriasis using prodrugs of methyl hydrogen fumarate are disclosed. The methods comprise administering certain prodrugs of methyl hydrogen fumarate. The methods are able to achieve high blood plasma concentrations of the active metabolite, methyl hydrogen fumarate, without causing significant gastrointestinal irritation. New prodrugs of methyl hydrogen fumarate are also disclosed.

Claim (Index 28):
The oral pharmaceutical formulation of  claim 16 , wherein said compound exhibits the following characteristics or effect:\n oral administration of the MHF prodrug(s) can be sufficient to obtain (i) a therapeutic concentration of MHF in blood plasma of the patient of at least 1.0 m/ml at a time within 24 hours after said oral administration; and (ii) an area under a concentration of MIHF in blood plasma versus time curve (AUC) of at least 12.0 \u03bcg\u00b7hr/ml over 24 hours after start of the oral administration.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 100.0
- Lexical Diversity: 1.65789
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13973456', '15395977', '13761864', '12544133', '13274284']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7780656958616788
- 35 USC 102 Novelty (BERT): 0.5176191325305215
- Combined Prediction Score: 0.7520210395285631
- Mean Citation Score: 271.159026
- Max Citation Score: 295.05405
- Similarity Product: 196.7371755822033

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test